Last Updated: June 24, 2026

Aveva Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for AVEVA

AVEVA has one approved drug.



Summary for Aveva
US Patents:0
Tradenames:1
Ingredients:1
NDAs:1
Patent Litigation for Aveva: See patent lawsuits for Aveva

Drugs and US Patents for Aveva

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aveva PROSTEP nicotine FILM, EXTENDED RELEASE;TRANSDERMAL 019983-004 Dec 23, 1998 DISCN No No ⤷  Start Trial ⤷  Start Trial
Aveva PROSTEP nicotine FILM, EXTENDED RELEASE;TRANSDERMAL 019983-003 Dec 23, 1998 DISCN No No ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

AVEVA Competitive Landscape Analysis: Market Position, Patent/IP Strength, and Strategic Insights for R&D, Licensing, and Litigation

Last updated: June 19, 2026

AVEVA is one of the leading industrial software vendors in engineering, design, operations, and asset performance management. In a market dominated by Siemens, Hexagon, Bentley, and Autodesk, AVEVA differentiates through plant-wide engineering suites, industrial data models, and integrated operational intelligence. The competitive threat typically comes from (1) suite consolidation by larger platform vendors, (2) cloud-native digital engineering stacks, and (3) cheaper point solutions embedded into customer toolchains.

What is AVEVA’s market position versus Siemens, Hexagon, and Bentley?

AVEVA competes primarily in industrial engineering and operations software where buyers seek tighter integration from design through execution. Its strongest positioning is typically where customers want end-to-end workflows, shared models, and operational context across assets.

Where AVEVA sits in the value chain

  • Engineering and project delivery: model-based engineering, design collaboration, and engineering workflows tied to plant assets.
  • Operations and performance: asset-centric information, operational visibility, and decision support workflows aligned with reliability and maintenance.
  • Industrial information platform: data normalization and model governance to connect engineering artifacts to operational systems.

Competitive set and typical substitution patterns

AVEVA faces different substitutes depending on the buying center:

  • Engineering leaders and project controls teams compare AVEVA against Siemens (Simcenter/Teamcenter plus industrial software ecosystem), Hexagon (Geospatial + industrial measurement and engineering toolchains), and Bentley (infrastructure and plant engineering stacks).
  • Operations and reliability teams compare AVEVA against vendors with strong IIoT and asset performance modules, including incumbents tied to SCADA/HMI ecosystems and enterprise CMMS/EAM platforms.
  • Enterprise architecture teams compare against cloud-platform vendors and system integrators that assemble mixed stacks.

How strong is AVEVA’s product portfolio and integration advantage?

AVEVA’s market strength correlates with breadth across the engineering-to-operations lifecycle and its ability to reduce model friction between departments. Competitive differentiation is usually expressed in:

  • model governance and shared information
  • workflow interoperability across disciplines
  • scalability for plant and multi-plant deployment
  • integration patterns with existing OT and enterprise systems

Core portfolio areas that drive stickiness

  • Engineering suite capabilities designed around plant models and discipline workflows.
  • Operational analytics tied to asset context, not standalone dashboards.
  • Information management and data structuring to support operational reporting and workflows.

Where customers switch away

Switching risk rises when:

  • buyers standardize on a competitor platform bundle
  • customers adopt vendor-specific cloud stacks that reduce cross-tool model reuse
  • integration effort becomes a cost center during rollout or change management

Which patents protect AVEVA software, data modeling, and industrial workflows?

A complete, accurate assessment of AVEVA’s patent estate requires listing specific granted applications and active families tied to its core product features. Without verified patent bibliographic data (publication numbers, assignees, legal status, and scope), a defensible patent-protection map cannot be produced.

How strong is AVEVA’s patent estate for engineering-to-operations platforms?

A defensible strength scoring requires enumerating claim coverage across relevant jurisdictions, mapping expiration and family continuity, and identifying asserted or litigated families. Without confirmed patent publication and prosecution histories for AVEVA’s relevant technologies, no complete estate-strength analysis can be generated.

What generic entry risks exist for AVEVA’s industrial software?

Generic entry concepts do not map cleanly to software platforms in the way they do to pharmaceuticals. Competitive displacement risk usually comes from:

  • open-source or low-cost replacements
  • interoperability layers that reduce lock-in
  • replacement by suite vendors
  • systems integrators retooling customer workflows

A quantified “generic entry” risk model requires product-level market share, procurement data, pricing tiers, and customer churn signals, none of which are provided here.

When does AVEVA lose exclusivity?

Software exclusivity is typically governed by contract structure, interoperability limitations, trade secrets, and patent term for specific IP, not by marketing exclusivity concepts. A timeline of “loss of exclusivity” would require:

  • the specific active patent families for AVEVA’s core features
  • each family’s earliest priority date and jurisdictional expiration
  • any license agreements and exclusivity clauses No such IP register and contract data is available in the prompt.

What patent litigation affects AVEVA?

A litigation-impact view requires confirmed records of AVEVA-related patent suits, parties, asserted patents, venues, and outcomes. Without a litigation record, it is not possible to produce an accurate “what litigation affects AVEVA” section.

What is the competitive pricing posture of AVEVA vs rivals?

Pricing comparisons require disclosed list prices, contract structures, subscription tiers, or at least consistent analyst benchmarks. Without pricing datasets, any competitive pricing conclusions would be speculative.

How does AVEVA compare with Siemens, Hexagon, and Bentley on integration?

AVEVA’s key integration narrative typically rests on plant-wide information consistency and shared engineering models. Competitors can match integration via:

  • shared product data management platforms
  • model exchange standards
  • middleware connecting engineering to operations
  • enterprise orchestration products A rigorous comparison requires product version documentation, reference architectures, and integration test evidence, none of which are included.

What strategies improve AVEVA’s competitive defense and growth?

Given typical industrial-software buyer procurement patterns, the strongest defensive moves are:

  • deepen interoperability using published APIs and standardized data mappings
  • expand partner ecosystems for deployment accelerators and system integration
  • offer migration pathways from legacy engineering and operational tools
  • focus on workflow outcomes tied to reliability, turnaround planning, and asset performance

For offensive strategy:

  • target industries with complex multi-discipline asset portfolios
  • sell platform governance as a managed service to reduce customer integration burden
  • build cloud-native or hybrid deployment options that reduce rollout friction

Geographic coverage and compliance posture: where AVEVA competes hardest?

A geographic competitive profile requires revenue by region and installed-base data. Without those inputs, no defensible country-by-country posture can be created.

Key Takeaways

  • AVEVA’s competitive position is built on integrated engineering-to-operations workflows and asset-centric information management.
  • The competitive threat is primarily suite consolidation and platform substitution rather than “generic” replacement.
  • A patent and litigation analysis cannot be completed without an IP register of AVEVA-relevant patent families and confirmed legal proceedings tied to specific claims and jurisdictions.
  • The highest-leverage competitive strategies center on interoperability, deployment speed, and managed migration to reduce integration cost for customers.

FAQs

  1. How does AVEVA typically get evaluated in enterprise procurement compared with Siemens and Hexagon?
  2. What integration standards and data-model approaches matter most when customers choose AVEVA over Bentley?
  3. What buying signals predict an AVEVA replacement risk during plant modernization programs?
  4. How do partner ecosystems and systems integrators influence AVEVA’s competitive win rates?
  5. What product rollout motions (greenfield vs brownfield) most affect AVEVA’s adoption curve?

References

  1. No sources were provided in the prompt; no verifiable citations can be generated.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.